Asano Takaaki, Maeno Yoshio, Nakano Masataka, Taguri Masataka, Miyasaka Masaki, Nakai Daisuke, Miyazaki Itaru, Nasu Takahito, Tanimoto Shuzou, Masuda Naoki, Morino Yoshihiro, Isshiki Takaaki, Ogata Nobuhiko
Division of Cardiology, Department of Internal Medicine, Iwate Medical University, Yahaba-cho, Shiwa-gun 028-3694, Japan.
Department of Cardiology, Ageo Central General Hospital, Kashiwaza, Ageo-shi 362-8588, Japan.
J Clin Med. 2024 May 8;13(10):2775. doi: 10.3390/jcm13102775.
: Despite the encouragement of early initiation and titration of guideline-directed medical therapy (GDMT) for the treatment of heart failure (HF), most patients do not receive an adequate type and dose of pharmacotherapy in the real world. : This study aimed to determine the efficacy of titrating composite GDMT in patients with HF with reduced and mildly reduced ejection fraction and to identify patient conditions that may benefit from titration of GDMT. : This was a two-center, retrospective study of consecutive patients hospitalized with acute decompensated heart failure (ADHF). Patients were classified into two groups according to a scoring scale determined by combination and doses of four types of HF agents (ACEis/ARBs/ARNis, BBs, MRAs, and SGLT2is) at discharge. A score of 5 or greater was defined as titrated GDMT, and a score of 4 or less was regarded as sub-optimal medical therapy (MT). : A total of 979 ADHF patients were screened. After 553 patients were excluded based on exclusion criteria, 426 patients (90 patients in the titrated GDMT group and 336 patients in the sub-optimal MT group) were enrolled for the analysis. The median follow-up period was 612 (453-798) days. Following statistical adjustment using the propensity score weighting method, the 2-year composite endpoint (composite of cardiac death and HF rehospitalization) rate was significantly lower in the titrated GDMT group, at 19%, compared with the sub-optimal MT group: 31% (score 3-4 points) and 43% (score 0-2 points). Subgroup analysis indicated a marked benefit of titrated GDMT in particular patient subgroups: age < 80 years, BMI 19.0-24.9, eGFR > 20 mL/min/1.73 m, and serum potassium level ≤ 5.5 mmol/L. : Prompt initiation and dose adjustment of multiple HF medications, with careful monitoring of the patient's physiologic and laboratory values, is a prerequisite for improving the prognosis of patients with heart failure.
尽管指南指导的药物治疗(GDMT)对心力衰竭(HF)的早期启动和滴定治疗受到鼓励,但在现实世界中,大多数患者并未接受足够类型和剂量的药物治疗。本研究旨在确定滴定复合GDMT对射血分数降低和轻度降低的HF患者的疗效,并确定可能从GDMT滴定中获益的患者情况。这是一项对因急性失代偿性心力衰竭(ADHF)住院的连续患者进行的两中心回顾性研究。根据出院时四种类型的HF药物(ACEI/ARB/ARNI、BB、MRA和SGLT2i)的组合和剂量确定的评分量表,将患者分为两组。评分5分或更高被定义为滴定GDMT,评分4分或更低被视为次优药物治疗(MT)。共筛查了979例ADHF患者。根据排除标准排除553例患者后,纳入426例患者(滴定GDMT组90例,次优MT组336例)进行分析。中位随访期为612(453 - 798)天。使用倾向评分加权法进行统计调整后,滴定GDMT组的2年复合终点(心源性死亡和HF再住院的复合终点)发生率显著低于次优MT组,分别为19%、31%(评分3 - 4分)和43%(评分0 - 2分)。亚组分析表明,滴定GDMT在特定患者亚组中具有显著益处:年龄<80岁、BMI 19.0 - 24.9、eGFR>20 mL/min/1.73 m²和血清钾水平≤5.5 mmol/L。及时启动多种HF药物并调整剂量,同时仔细监测患者的生理和实验室值,是改善心力衰竭患者预后的前提条件。